STOCK TITAN

Innate Pharma - IPHA STOCK NEWS

Welcome to our dedicated news page for Innate Pharma (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Innate Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Innate Pharma's position in the market.

Rhea-AI Summary
Innate Pharma reports positive final results of lacutamab TELLOMAK Phase 2 trial in Sézary syndrome, licensing of a fourth NK cell engager ANKET® by Sanofi, and other significant milestones achieved in 2023. The company's cash position stands at €102.3 million as of December 31, 2023, with a cash runway to the end of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.6%
Tags
earnings
-
Rhea-AI Summary
Innate Pharma SA executives to participate in the 2nd Annual H.C. Wainwright Cell Therapy Virtual Conference on March 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.67%
Tags
conferences
-
Rhea-AI Summary
Innate Pharma SA (IPH; IPHA) announced a conference call on March 21, 2024, to discuss financial results for the full year ending December 31, 2023. Key participants include the CEO, CMO, COO, CFO, and President of US Operations. The event will be live webcasted and accessible via telephone. A replay will be available on the company's website for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
earnings
Rhea-AI Summary
Innate Pharma announces that its preclinical asset IPH45, a topoisomerase I inhibitor ADC targeting Nectin-4, has been selected for oral presentation at the AACR Annual Meeting 2024. The abstract highlights promising preclinical data showing effective tumor growth inhibition and a favorable safety profile, advancing IPH45 towards clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
conferences clinical trial
-
Rhea-AI Summary
Innate Pharma SA initiates Phase 1/2 trial for IPH6501, a CD20-targeting tetraspecific NK cell engager for B-cell Non-Hodgkin's Lymphomas. The study aims to enroll up to 184 patients, with the first patient already dosed. IPH6501 co-engages CD20 on malignant B cells and three NK cell receptors, enhancing cytotoxic activity. The IL-2 variant in IPH6501 provides proliferation signals to NK cells, offering a promising alternative to T cell therapies. Dr. Sonia Quaratino and Dr. Lorenzo Falchi express optimism about IPH6501's potential in treating refractory B-cell NHL.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
clinical trial
-
Rhea-AI Summary
Innate Pharma (IPH; IPHA) to participate in Leerink Partners Global Biopharma Conference 2024 in Miami, Florida from March 11-13, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
conferences
Rhea-AI Summary
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) releases its total number of shares outstanding as well as its voting rights as at January 1, 2024: Total number of shares outstanding: 80,860,563 ordinary shares, 6,509 Preferred Shares 2016, 7,581 Preferred Shares 2017. Total number of theoretical voting rights: 81,617,753. Total number of exercisable voting rights: 81,599,178.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
Rhea-AI Summary
Innate Pharma SA (IPH; IPHA) announced that the FDA has lifted the partial clinical hold on the lacutamab clinical program. The hold was placed after a patient death in the TELLOMAK study, initially thought to be due to a rare hematologic disorder. The FDA determined the death was related to disease progression and unrelated to the treatment. The lacutamab program continues following positive results in Sézary syndrome and plans to share final data in Mycosis Fungoides.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
none
-
Rhea-AI Summary
Innate Pharma SA (IPH; IPHA) strengthens leadership and corporate governance with the appointment of two new Executive Board members. Hervé Brailly, interim CEO, welcomes Arvind Sood as EVP, President of US Operations, and Dr. Sonia Quaratino as EVP, Chief Medical Officer to the Executive Board. Yannis Morel broadens his remit to Chief Operating Officer. The Company is positioning itself for future success by expanding its footprint in the US market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
management
Rhea-AI Summary
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) and Sanofi (NASDAQ: SNY) announced that Sanofi has exercised its option to license a natural killer (NK) cell engager program from Innate’s ANKET® platform. Sanofi will be responsible for all development, manufacturing, and commercialization of the program. Innate will receive a €15m payment for the exercise of this option and is eligible for up to €1.35bn in total milestones plus royalties on potential net sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.8%
Tags
none
Innate Pharma

Nasdaq:IPHA

IPHA Rankings

IPHA Stock Data

192.40M
30.48M
0.1%
0.1%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
France
Marseille

About IPHA

innate pharma s.a. is a clinical-stage biotechnology company dedicated to improving cancer treatment and clinical outcomes for patients through first-in-class therapeutic antibodies that harness the innate immune system. innate pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells. the company's broad pipeline includes four first-in-class clinical stage antibodies as well as preclinical candidates and technologies that have the potential to address a broad range of cancer indications with high unmet medical needs. innate pharma has pioneered the discovery and development of checkpoint inhibitors, with a unique expertise and understanding of natural killer cell biology. this innovative approach has resulted in major alliances with leaders in the biopharmaceutical industry including astrazeneca, bristol-myers squibb, novo nordisk a/s and sanofi. innate pharma